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Background: Patients with neurologic diseases often have neurogenic detrusor overactivity (NDO), which can result
in a loss of voluntary bladder control and uncontrollable urinary incontinence (UI).The impact of UI due to NDO on
patients’ lives has not been well studied. The objective of this review was to assess the health-related quality of life
(HRQoL) and economic burden in patients with urgency UI due to NDO in select countries in North America, the
European Union, Asia, and Australia.
Methods: Systematic literature searches and reviews of articles published in English (January 2000 to February
2011) were conducted using MEDLINEW, EMBASEW, and the Cochrane Library. Studies assessing the impact of UI on
HRQoL of patients with an underlying neurologic condition of interest (i.e., multiple sclerosis, spinal cord injury,
Parkinson’s disease, stroke, or spina bifida) were included. Economic studies in urgency UI also were included.
Results: Of 876 citations generated in the initial search, a total of 27 articles were deemed relevant: 16 articles presented
HRQoL data and 11 articles presented information on the economic burden of UI. Humanistic studies used a range of
HRQoL instruments to measure HRQoL burden, and the economic studies included different cost components to
quantify the economic burden, making meaningful comparisons challenging. Despite this heterogeneity, the literature
suggests that HRQoL in patients with UI due to NDO is worse than patients with UI in general or those with the same
underlying neurologic condition without UI. In addition, urgency UI also results in substantial economic costs.
Conclusions: Incontinent patients with underlying neurologic conditions have impaired HRQoL as well as substantial
economic burden attributable to UI due to NDO. There is a need for urgency UI treatments that improve HRQoL of
these patients and alleviate the economic burden of this condition.
Keywords: Urinary incontinence, Overactive bladder, Quality of life, Burden of illness, Health resources,
Economic burdenReview
Background
Patients with neurologic diseases such as multiple scler-
osis (MS) or spinal cord injury (SCI) often have a loss of
bladder control. This may result from involuntaryblad-
der contractions during the filling and storage phase of
the urination process, which is referred to as neurogenic* Correspondence: Khalaf_Kristin@Allergan.com
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reproduction in any medium, provided the ordetrusor overactivity (NDO) [1,2]. Symptoms of NDO
mirror those of overactive bladder (OAB), and include
urgency, urinary frequency, and urgency urinary incon-
tinence (UI), and may lead to serious medical sequelae
such as urinary tract infections and skin decubiti if inad-
equately managed [3-8].
Although numerous studies have quantified both the
economic and quality-of-life impact of OAB and general
incontinence symptoms, the impact of UI specifically
due to NDO has not been well characterized. Due to
their underlying neurologic conditions, patients with UItd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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than their otherwise healthy counterparts, and urgency
UI due to NDO is secondary to numerous neurologic
conditions that vary not only with respect to their pres-
entation but also in the characteristics of affected pa-
tients. A better understanding of the negative effects of
urinary symptoms on the economic outcomes and qua-
lity of life of patients with neurologic conditions is im-
portant in order to optimize treatment when potential
pharmacologic therapies may be appropriate, as the uti-
lization of outcomes data together with clinical as-
sessments best reflects the patients spectrum of disease
[1]. A systematic review of the published literature was
therefore conducted in order to describe the health-
related quality of life (HRQoL) and estimate the per-
patient economic burdens of urgency incontinence due
to NDO secondary to any of the following neurologic




Literature searches were conducted using MEDLINEW,
EMBASEW, and the Cochrane Library, which included
Cochrane Reviews, the Database of Abstracts of Reviews
of Effects (DARE), the Cochrane Central Register of
Controlled Trials (CENTRAL), the Health Technology
Assessment Database, and the National Institute for
Health Research Economic Evaluation Database (NHS
EED), to identify relevant articles that assessed the
humanistic and economic burden of UI due to NDO.
Relevant search terms for UI, such as incontinence, neu-
rogenic bladder, detrusor overactivity, and urgency, were
cross-referenced with outcome concepts (HRQoL bur-
den of illness and economic burden of illness) as ap-
propriate and with terms for the following underlying
neurologic conditions: MS, SCI, Parkinson’s disease, stro-
ke, and spina bifida. The search was limited to titles and
abstracts of human studies conducted in the United
States, the European Union 5 (EU 5: United Kingdom,
France, Germany, Italy, and Spain), Canada, Australia,
Thailand, South Korea, and Taiwan that were published in
English from January 2000 to February 2011. Selected
studies were ranked and assigned levels of evidence in ac-
cordance with the 2011 Oxford Centre for Evidence-
Based Medicine (CEBM) Levels of Evidence [9].
Study selection criteria
The search failed to identify burden of illness studies in
individuals with urodynamically confirmed NDO. Since
the literature suggests that UI among patients with un-
derlying neurologic conditions is attributable to detrusor
overactivity in the majority of cases, [10,11] the inclusion
criteria were slightly modified to include any burden ofillness studies in individuals with UI who had one of the
underlying neurologic conditions of interest.
In addition, the search identified only one interven-
tional study that assessed the economic burden of UI
specifically resulting from NDO.assessed the economic
burden specifically resulting from Therefore, these inclu-
sion criteria were modified to include any economic stu-
dies that assessed the economic burden of UI in general
and reported per-patient costs of care, as it was de-
termined that costs associated with leakage of urine,
irrespective of the underlying cause, would not differ
substantially by UI etiology. Recognizing that the UI
population is much larger and distinct from the NDO-
related UI population, only studies that presented per-
patient costs (vs. total costs for the UI population) were
ultimately included to conservatively assess the econo-
mic impact of UI on patients with NDO.
Literature selection and data extraction
The selection and appraisal of the titles, abstracts, and
literature were completed by two independent reviewers.
The reviewers documented the reason for exclusion for
every article that was not included in the analysis. Any
discrepancies in the selection and appraisal of the ar-
ticles were discussed between the reviewers and resol-
ved with the help of a third reviewer, where necessary.
Full articles were retrieved for the remaining documents
from this round of review. The inclusion/exclusion cri-
teria were applied to the review of full articles and key
relevant articles were selected for data extraction. The
key data, including a description of the study design, stu-
dy population, baseline characteristics, and a summary
of the economic and humanistic burden measures and
related findings, were extracted from each publication.
In order to compare costs related to the per-patient
economic burden of UI reported across studies from dif-
ferent years and in various countries, all non-acute costs
were annualized by multiplying weekly costs by 52 and
daily costs by 365, and all costs were converted to US
dollars for the year 2010, using consumer price indices
for medical resources [12-14].
Results
The initial literature search generated 876 citations
(Figure 1). After title review, 591 articles were excluded;
the majority of these articles were clinical trials evaluat-
ing various treatments, which focused primarily on clin-
ical endpoints, rather than HRQoL or economic burden.
Abstracts of the remaining articles were then review,
after which 92 articles were considered relevant and 87
full-text articles were retrieved (four articles were not
available in English and one article was not available
from the library or electronic source). Of 87 references,
60 were further excluded because they were not for the
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or economic burden of UI. Figure 1 presents the article
selection criteria for the publications identified from the
MEDLINEW, EMBASEW, and the Cochrane Library data-
bases, along with details regarding exclusion criteria.
A total of 27 full text articles fulfilled all of the revised
criteria and are summarized in this literature review. No
studies assessing the HRQoL burden in patients with UI
due to urodynamically confirmed NDO were identified.
Sixteen references on the impact of UI on HRQoL in in-
dividuals with MS, SCI, Parkinson’s disease, stroke, or
spina bifida were identified (Additional file 1: Table S1).
As mentioned above, our initial search identified only
one study in patients with SCI, spina bifida or MS on the
per-patient economic burden of UI in patients with NDO
[15]. Our modified search identified 10 additional studies
that presented patient-level information surrounding the
economic burden of UI in general (Table 1).
Impact of UI on the HRQoL of individuals with underlying
neurologic conditions
Studies that assessed the impact of UI resulting from un-
derlying neurologic conditions on the HRQoL of indi-
viduals used a variety of generic and/or disease-specific
instruments and focused on different domains of HRQoL.
However, the studies generally indicated that UI negatively
affects HRQoL among individuals with underlying neuro-
logic conditions of interest (Additional file 1: Table S1).
Multiple sclerosis
Four studies provided information on the impact of UI
in individuals with MS [16-19]. Two of these studies
[16,17] assessed general health status as measured by the
Medical Outcomes Study 36-Item Short Form Health
Survey (SF-36) [20], a subjective measure of health status
across eight domains with scores ranging from 0 (worse
HRQoL) to 100 for each scale. The conclusions of the two
studies differed, with the first study concluding that UI
was not associated with SF-36 scores (independent of the
impact of MS itself ) [16] while the second study found
that for the physical functioning and role-emotional do-
mains, those with UI had lower SF-36 scores compared to
those without UI (physical functioning: 42.67 vs. 62.42;
role-emotional: 27.13 vs. 42.39, respectively; p < 0.05) [17].
The third study assessed the impact of bladder problems
on HRQoL in individuals with MS using disease-specific
measures, including the Incontinence Impact Question-
naire (IIQ-7), Urogenital Distress Inventory (UDI-6), and
American Urological Association (AUA) Symptom Index.
[18] Approximately 96% of individuals reported having
bladder problems, with 41% reporting they were “moder-
ately” or “greatly” bothered by frequent urination, 39% by
UI associated with urgency, and 26% by activity. Further-
more, a substantial number of patients reported“somewhat” or “a great deal of” interference caused by
bladder problems, and urinaryu problems impacted emo-
tional health (31%), ability to perform household chores
(22%), and physical recreation (28%). In addition, almost
half of the patients reported that they would feel “mostly
dissatisfied,” “unhappy,” or “terrible” if they had to spend
the rest of their lives with their current urinary condition.
These results indicate that UI is not only bothersome and
troubling to people with MS but also results in substantial
disability.
The fourth study compared HRQoL of OAB patients
with MS (OAB+MS group) versus OAB patients with-
out MS (OAB group) using select domain scores of
the Kings Health Questionnaire (KHQ; another disease-
specific HRQoL measure) and found that urinary symp-
toms had more impact on HRQoL in the OAB+MS group
compared with the OAB group [19]. KHQ scores were
significantly higher (indicating greater impairment) in the
OAB+MS versus the OAB groups (respectively) in five do-
mains: general health perception (56.3 vs. 33.3, p = 0.02),
role limitations (50 vs. 36.1, p = 0.03), physical limitations
(56.3 vs. 33.3, p = 0.02), social limitations (45.8 vs. 18.5,
p = 0.002), and urinary symptoms (17 vs. 14, p = 0.05). Pa-
tients in the OAB+MS group, however, felt that their blad-
der symptoms had a lesser impact on their lives than
those in the OAB group and perceived their incontinence
symptoms to be less severe compared with the OAB
group. Urinary symptoms in both groups were also shown
to adversely affect including physical activities, sleep/en-
ergy, emotions, and relationships; however, this impair-
ment was generally greater in patients with MS.
Spinal cord injury
Four studies were identified assessing the impact of UI
among patients with SCI [21-24]. The first study com-
pared SF-36 scores of 132 incontinent SCI patients using
clean, intermittent catheterization (CIC) with those of
the general population [22]. Incontinent SCI patients
had significantly lower SF-36 scores across all domains
(except for the energy and vitality scores in female cases)
when compared with the general population (p < 0.05).
The greatest detriments in incontinent SCI patients were
in the physical functioning domain for both male and fe-
male patients (male patients vs. controls, 18.4 ± 3.2 vs.
85.3 ± 1.7, respectively, p < 0.001 and female patients vs.
controls, 28.3 ± 4.4 vs. 72.0 ± 2.3, respectively, p < 0001).
Scores for all other domains were also lower among SCI
patients compared with the general population (detri-
ments ranged from 7.7 to 55.6 points).
Similar results were reported in a separate cross-sec-
tional study in 142 SCI patients in the UK [21]. SF-36
scores and KHQ scores of SCI patients with normal
voiding function were compared with scores of incon-
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Figure 1 Article selection flow chart for UI due to NDO publications. Reasons for exclusion: A. Editorials, letters, case reports, lectures, news,
comment, legal cases, newspaper article, technical report, and clinical trial studies. B. Studies on urinary incontinence (UI) due to idiopathic
detrusor overactivity or idiopathic overactive bladder.* C Studies in patients with neurogenic detrusor overactivity (NDO) with urgency but
without UI (DRY). D. Studies on stress UI. E. Studies in patients with NDO that is not associated with multiple sclerosis (MS), spinal cord injury
(SCI), Parkinson’s disease (PD), stroke, or spina bifida (SB). F. Studies in children or adolescents (<18 years of age) with MS, SCI, PD, or stroke.
G. Studies in patients with overactive bladder (OAB) that do not report results specific to urgency UI. H. Studies not requiring patients to have
urgency. I. Small (n < 30) case series. J. Studies from countries other than the US, EU 5 (UK, France, Germany, Italy and Spain), Canada, Australia,
Thailand, South Korea, and Taiwan. K. Studies that do not specifically discuss the economic or humanistic burden of UI due to NDO from MS, SCI,
PD, stroke, or SB. Note: Studies in children or adolescents (<18 years of age) diagnosed with SB were included in the systematic review. * Did not
apply to economic studies.
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Table 1 Studies on the economic burden associated with incontinence
Citation; CEBM Evidence
grade [9]
Study design/methodology Cost data source Country Populations
Frantz et al. 2003 [39]; 2 Secondary data analysis Medical records US Residents of long-term care facility
• N = 63
• Mean age 87 ± 7 yr
• 77% were female
• 54% were incontinent
Green et al. 2003 [34]; 3 Retrospective analysis Registry Australia 6773 episodes of care provided to 6455
rehabilitation and geriatric evaluation and
management patientsNew Zealand
Irwin et al. 2008 [36]; 3 Economic cost of illness model; included
costs for 2002 ICS-defined OAB and urgency
UI-related comorbidities and nursing home costs
Economic model Canada EPIC survey population with OAB or urgent UI
Germany




Morris et al. 2005 [33]; 3 Prospective burden of illness study Prospective chart data Australia Incontinent patients
• Mean age 85 (range 74–91) yr
Papanicolaou et al. 2005 [35]; 3 Prospective urinary incontinence research (PURE)
is a non-interventional, longitudinal, prospective,
observational, multicentre, multinational study to
determine the direct cost for patients with UI
Prospective survey data Germany Patients with UI
Spain • Germany: n = 2696, mean age 65.1 ± 13.4 yr
UK/Ireland • Spain: n = 2127, mean age 57.9 ± 12.7 yr
• UK/Ireland: n = 1070, mean age 60.1 ± 14.3 yr
Prasopsanti et al. 2007 [41]; 3 Economic model using diagnostic and treatment
algorithms from clinical practice guidelines and
current disease prevalence data
Economic model Thailand Patients with UI (prevalence estimates used in
model derived from elsewhere)
Shih et al. 2003 [40]; 3 Prospective study Prospective survey data US Patients with UI in long-term care facilities
Subak et al. 2006 [42]; 3 Cross-sectional study Prospective survey data US Women with UI
• N = 293
• Mean age 56 ±11 yr
Tediosi et al. 2000 [37]; 3 Cross-sectional study/home interview with costs
quantified for stress UI and other types of UI
separately
Interview data and retrospective database
(Italian National Health Service tariffs)
Italy Women with UI
























Table 1 Studies on the economic burden associated with incontinence (Continued)
Thom et al. 2005 [38]; 3 Database study Retrospective database US Women with UI
• N = N/A (combination of large public and private
population data sources, including CMS, MEPS, NHANES,
NCHS, VA, NACHRI, and MarketScan)
• Age >60 yr
Wefer et al. 2010 [15]; 2 Multicentre, cross-sectional, retrospective cohort
study




• N = 214
• Mean age 38 (14.8) yr
UI = urinary incontinence; OAB = overactive bladder; CEBM = Oxford Centre for Evidence-Based Medicine; CMS = Centers for Medicare and Medicaid Services; MEPS = Medical Expenditure Panel Survey;
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http://www.hqlo.com/content/11/1/13bladder management. Incontinent SCI patients scored
significantly lower than continent patients on the physi-
cal functioning and mental health domains of the SF-36,
as well as on the physical component summary (PCS) and
mental component summary (MCS) scores (p < 0.05).
Moreover, incontinent SCI patients who were using CIC
by an attendant, indwelling transurethral catheterization,
or indwelling suprapubic catheterization had the lowest
mental health domain and MCS scores compared with
SCI patients who were continent or SCI patients using
other forms of bladder management, such as self-CIC, re-
flex trigger, or bladder expression. KHQ scores corrobo-
rated these findings. SCI patients without UI had higher
KHQ scores compared with incontinent patients requiring
bladder management, with significant differences observed
in the physical limitations, social limitations, personal re-
lationships, and emotions domains (p < 0.05). The fre-
quency of UI also had a substantial impact on HRQoL.
Worse HRQoL scores were associated with increased fre-
quency of incontinence, and SCI patients who experienced
daily UI episodes had the worst SF-36 and KHQ scores.
Mental health domain and MCS scores significantly de-
creased as the frequency of UI episodes increased (mental
health: 77.4, no incontinence vs. 60.7, daily incontinence;
p = 0.01; MCS: 42.2, no incontinence vs. 27.7, daily incon-
tinence; p = 0.01). Significantly worse KHQ scores were
also observed in the incontinence impact, social limita-
tions, emotions, and severity measures domains as the fre-
quency of UI increased (p < 0.05).
Baseline data from a recent interventional, randomized
controlled trial in SCI patients with incontinence due to
NDO further suggest that the HRQoL of these patients
is greatly impaired [23]. HRQoL was assessed with the
Incontinence Quality of Life (I-QOL) questionnaire and
SF-36 before treatment with botulinum toxin A. I-QOL
is a 22-item disease-specific HRQoL questionnaire with
possible scores ranging from 0 (worse HRQoL) to 100
(higher HRQoL). At study baseline, the mean I-QOL
score was 44 (range 9–82), with the greatest decre-
ment noted on the social embarrassment domain (mean
score = 33), and SF-36 scores ranged from 51 to 65, ex-
cept for physical functioning, the average of which was
32. TheT authors noted that the physical functioning
score might be more reflective of the physical impact of
the neurologic condition rather than that of incontin-
ence. However, significant improvements in the role-
physical and role-emotional domains of the SF-36 were
observed following botulinum toxin A treatment, imply-
ing that some degree of their general HRQoL impair-
ment could be attributed to incontinence.
In addition to physical, mental, and psychological im-
pairments, the final study in SCI patients suggests that UI
also negatively affects sexual life [24]. Study participants
with traumatic SCI reported via questionnaire that UIcaused inconvenience with regards to sexual life. Those
reporting that UI was more of an inconvenience in their
lives were also more dissatisfied with their sexual life com-
pared with those reporting that UI was less of an incon-
venience. This correlation was significant for men but not
for women (Spearman’s rho = 0.29, p = 0.021 vs. –0.18,
p = 0.236, men vs. women, respectively).
Parkinson’s disease
Two relevant studies that assessed the impact of UI
in people with Parkinson’s disease were identified. One
study in Italy used the symptom bother component of
the OAB questionnaire Short Form (OAB-Q SF) to as-
sess the frequency and bother of frequency, urgency,
nocturia, and incontinence symptoms in patients with
Parkinson’s disease compared with healthy controls [25].
Scores ranged from 8 to 48, with higher scores indicat-
ing greater symptom bother. The study found that pa-
tients with Parkinson’s disease and urinary symptoms
were significantly more bothered compared with healthy
controls without Parkinson’s disease or urinary symp-
toms (18.71 vs. 12.37, respectively; p = 0.0001).
A study in Canada compared HRQoL of patients with
Parkinson’s disease and UI versus Parkinson’s patients
without UI [26]. The study utilized data from the Canadian
Community Health Survey in which health status was
assessed using the Health Utilities Index Mark 3 (HUI3), a
31-item questionnaire that assesses usual health status
with the following eight attributes: vision, hearing,
speech, ambulation, dexterity, emotion, cognition and
pain, and discomfort. HUI3 scores range from −0.36
(worst possible health) to 1.0 (1.0 = perfect health). Over-
all utility scores were significantly lower in persons afflic-
ted with both Parkinson’s disease and UI compared with
those with Parkinson’s disease who did not have UI (0.39
vs 0.61, respectively, p < 0.05) or the general population
(0.39 vs 0.83, respectively, p < 0.05). Furthermore, clinic-
ally important and statistically significantly lower scores
were reported for the ambulation (−0.22 [CI −0.42 to
−0.02, p < 0.05]), and emotion (−0.28 [CI −0.43 to −0.12,
p < 0.05]) attributes by respondents with Parkinson’s dis-
ease and UI compared with those who were continent.
The study thus suggests that UI has detrimental effects on
both the physical and mental health of patients with
Parkinson’s disease.
Stroke
Five studies in stroke patients with UI were identified,
which suggest that incontinent stroke patients have im-
paired functioning, lower life satisfaction, and higher
rate of institutionalization compared with stroke patients
who are continent.
Edwards et al. [27] interviewed 361 individuals 6
months post stroke and evaluated the impact of UI on
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all, 16% of individuals were incontinent at 6 months,
and these individuals were more impaired with respect
to basic and instrumental Activities of Daily Living
(ADL) scales. Incontinent stroke survivors were signifi-
cantly less independent with respect to basic self-care,
functional communication, and cognition compared with
continent survivors (p < 0.0001), as measured by the
Functional Independent Measure (FIM). Incontinent in-
dividuals also experienced significantly lower HRQoL
and well being than continent individuals, as assessed by
all other measures, and survivors had significantly lower
emotional well-being (SF-12 MCS score) and signifi-
cantly lower levels of life satisfaction (as measured by
the Reintegration to Normal Living Index, RNL) com-
pared with continent individuals (p < 0.0001). On aver-
age, incontinent individuals retained only 40% of their
pre-stroke activities, whereas continent individuals retai-
ned 70%. UI in stroke patients was thus associated with
greater dependence in basic and instrumental ADL, de-
creased participation in normal living, and lower life sat-
isfaction. In a cross-sectional, clinical survey conducted
in patients at least 1 month after their incident stroke
(n = 407) at an acute stroke and neurological unit in
Denmark [28], found that activity limitations were closely
related to incontinence. Mobile velocity was significantly
associated with severity of urinary symptoms (mean effect
= 0.37, p = 0.01), and low Barthel Index (a measure of dis-
ability status) scores and reduced mobility velocity in-
creased the risk of the prevalence (OR = 2.08, p = 0.03,
and OR = 1.87, p = 0.05, respectively) and severity (mean
effect = 0.21, p = 0.03 and mean effect = 0.22, p = 0.04,
respectively) of incontinence symptoms.
The remaining three studies assessed the impact of UI
on long-term outcomes in stroke patients, including dis-
ability, rate of institutionalization, and mortality [29-31].
Kolominski-Rabas et al. [29] reported that, according to the
Barthel Index, patients who were incontinent after a stroke
were severely (39%) or moderately (18%) disabled at 2 years,
whereas those who were continent after their strokes were
only mildly disabled (26%) or independent (51%).
The rate of institutionalization among incontinent
stroke patients ranged from 34% at 3 months post stroke
[30] to 45% at 12 months post stroke [29], and was
found to be significantly higher among incontinent stroke
patients institutionalized at 1 year (45%) compared with
those who were continent (5%; p = 0.001). [31] The risk of
mortality at 2 years was also greater among stroke patients
with UI compared with those without UI (odds ratio 4.43;
95% CI: 1.76 to 11.2; p = 0.002) [31].
Spina bifida
The literature search identified two studies that assessed
the impact of UI on HRQoL in people with spina bifida;however, neither study found a strong association be-
tween UI and HRQoL.The study by Valtonen et al. [24]
(described above, which assessed sexual satisfaction and
level of inconvenience due to UI among SCI patients)
also assessed the impact of UI on the sexual life of in-
dividuals born with meningomyelocele and found that
although UI caused some inconvenience, this inconve-
nience did not affect sexual satisfaction. The only other
study that assessed the relationship between UI and
HRQoL in spina bifida was a cross-sectional study in
460 patients at six centers in France using the SF-36 and
VSP (Vecu et santé percu, a French generic HRQoL in-
strument) [32]. HRQoL scores in incontinent adults with
spina bifida were not significantly different from those
patients without UI, except for the bodily pain domain
of the SF-36, in which the continent patient group had a
higher score (p = 0.05). No significant differences were
observed in the VSP scores among adolescent patients
with UI compared with those without UI [32].
Economic burden of UI
Our search identified one article that assessed the eco-
nomic burden of patients with urodynamically confir-
med NDO, and 10 articles that presented per-patient
costs of UI in the general population, 2 of which re-
ported results of subgroups of patients with neurologic
disease [33,34] (Table 1). These studies were diverse in
terms of perspective (payer, provider, patient, society),
the type of data used (electronic medical records,
surveys, interviews, model), cost components assessed
(labor costs, nursing home costs, office visits, surgery,
medications, diagnosis, pad usage), country of data
origin (US, Australia, Italy, Spain, Germany, Sweden,
UK, Thailand, Ireland), and study design (retrospect-
ive, cross-sectional, prospective). The heterogeneity of
these economic studies did not allow for direct compari-
sons of findings across patient populations or countries,
yet taken together, they suggest that UI results in signifi-
cant economic burden from the perspective of the payer,
provider, patient, and society as a whole.
One study found the total annual per patient cost of
UI to be $613.10 in Germany, $779.76 in Spain, and
$427.38 in the UK/Ireland when medication, incontin-
ence products, clinic/physician visits, and hospital stays
related to surgical interventions for incontinence were
included. The highest contribution to the overall cost
was pad usage in Germany (51%), diagnostic procedures
in Spain (27%), and health care provider visits in the
UK/Ireland (27%) [35]. In another cross-sectional, po-
pulation-based survey conducted in Canada, Germany,
Italy, Sweden, and the UK, direct medical cost estimates
(US$) for physician office visits and surgery related to UI
from the payer perspective ranged from $62.05 (in the
UK) to $259.20 (in Spain) per patient per year in Europe
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areas across Italy found that the most burdensome costs
associated with UI from the Italian National Health
Service was for diapers, which was estimated to be
$148.30 annually [37]. These wide ranges can be attrib-
uted to the heterogeneity with respect to the different
types of medical resources incorporated into the cost es-
timates for each study and medical resource utilization
patterns across different countries.
The one study that assessed the economic impact of
NDO suggests that direct costs of conservative care per
patient in European countries may be higher in patients
with UI due to NDO compared with patients with UI in
general or due to other causes [15]. In this study, which
evaluated medical resource use before and after treat-
ment with botulinum toxin A in patients with NDO, the
direct costs of NDO (reported from a third-party payer
perspective prior to treatment) included urinary tract in-
fection (UTI) pharmacotherapy and incontinence aids
(pads, urinary reservoirs).Annual per-patient pharma-
cotherapy costs for UTI were calculated to be $230.10,
whereas incontinence aids were calculated at $2.97 per
patient per day, which could be as much as $1,085.68
per year if extrapolated to annual cost in US dollars. The
estimated annual payer costs per patient for pad usage
was $727.02, which is much higher compared with pad
costs reported in other European countries (Table 2) [15].
Irwin et al. [36] reported costs from the payer perspec-
tive in various countries reporting annual direct costs
for OAB and urgency UI. Associated costs included phy-
sician office visits, hospital outpatient services, surgeries,
emergency room services, nursing home care, conserva-
tive care and devices, pad usage, and medications for
symptoms of OAB, including UI. Annual payer costs per
patient for incontinence pad usage ranged from $72.97
(in the UK) to $152.24 (in Spain). The study also repor-
ted per-patient costs for UTIs, skin infections, fractures,
and nursing home admissions associated specifically
with urgency UI. The annual costs per patient for ur-
gency UI–related comorbidities ranged from $10.12 (in
Spain) to $50.61 (in Sweden), whereas the annual urgen-
cy UI–related nursing home costs per patient ranged
from $43.37 (in Spain) to $2,284.22 (in Italy).
When acute hospitalization and long-term care costs
are added, the annual cost estimates increase further for
patients with UI. A study evaluating the cost of UI in 54
subacute medical facilities in Australia and New Zealand
found that stroke patients with high FIM motor scores
were more expensive to treat if they were incontinent
[34]. Another study conducted among a consecutive se-
ries of patients admitted to one of two sub-acute care
facilities in Australia who had UI found that the total
median daily cost of caring for UI among patients with
UI of neurological origin was $19.76 [33]. One study inthe United States reported that a payer spends as much
as $12,357.43 per female UI patient annually for hos-
pitalizations, physician office visits, outpatient services,
and emergency department services, with hospitalization
accounting for a majority of the costs [38]. Two other
studies assessed the provider costs associated with UI in
patients in long-term care facilities in the United States.
Franz et al. [39] reported that 6-month nursing staff costs
were $2,416.94 per UI patient. Six-month incontinence
management costs per patient were also substantial, with
toileting (time spent to toilet a patient by a nursing assist-
ant) accounting for the highest cost component (Table 2).
Shih et al. [40] analyzed the annual incremental cost of
labor associated with UI in the long-term facilities alone
and found that the annual cost of labor per UI patient to
be $6,741.87.
Few studies reported per-patient costs for UI from the
societal or patient perspective. A study of costs associ-
ated with OAB, including UI, in Thailand reported that
the weekly cost for pad usage was $4.45 for a patient
with UI, which, if extrapolated to annual cost, could be
as much as $232.20 per year [41]. In the United States,
the weekly cost for personal care for a patient with UI
(includes pads, paper towels, laundry, and dry cleaning)
was $7.90, which, if extrapolated to annual costs, could
be as high as $412.20 per year [42].
Discussion
To our knowledge this is the first study to characterize
the HRQoL and economic burden of UI in patients
with different underlying neurologic conditions. We found
that UI in individuals with MS, SCI, Parkinson’s disease,
and stroke has a substantial negative impact on pa-
tients’ HRQoL. Physical, mental and psychological impair-
ments were consistently observed, with patients reporting
detriments in physical function, emotional well being, and
social relationships. UI also had a negative effect on the
sexual lives of patients with neurologic conditions, and
may adversely affect long-term outcomes. Not surpris-
ingly, we also found that incontinent individuals with un-
derlying neurologic conditions also typically report worse
HRQoL compared with their continent counterparts and
the general population.
Three studies suggested that UI has little or no impact
on the HRQoL of patients with MS or spina bifida
[16,24,32]. Two of these studies used the SF-36, which
suggests that a general HRQoL instrument may not al-
ways be sensitive to capturing the impact of UI in popu-
lations that already have very debilitating conditions.
Another study which used the KHQ reported that in-
continent MS patients did not consider their incon-
tinence to be severe [18]. This could be attributed to an
accommodation that occurs in patients with chronic
conditions such as MS. These patients often need to
Table 2 Total costs per patient, associated with incontinence in general
Citation Country Perspective Time-
frame
Cost components reported Cost
year
UI costs Inflated 2010 Costs per year
(2010)Total costs
Labor Costs
Green 2003 [34] Australia,
New Zealand
Provider 1 day Rehabilitation staff 1996 $185.60/day AUD $267.40/day AUD *
Geriatric evaluation staff $164.62/day AUD $237.27/day AUD *
Morris 2005 [33] Australia Provider 1 day Nursing staff supervision 2003 $32.4 AUD $39.42 AUD *
Frantz et al. 2003 [41] US Provider 1 day Nursing staff supervision 1995 $112 $197.30 $72,014.50




Prasopsanti et al. 2007 [41] Thailand Society 1 yr Incremental labor costs in LTC 2002 $4.52/shift $6.15/shift $6,741.87/yr
$13.57/day $18.56/day
$4,957/yr $6,741.87/yr
















Papanicolaou 2005 [35] Germany Payer 1 yr Diagnosis 2004 €42 €46.14 $61.27 USD
Spain Diagnosis €186 €216.12 $286.98
UK/Ireland Diagnosis €6 €7 $9.30
Tediosi 2000 [37] Italy Payer 1 yr Diagnosis 1997 L76.142 L100.27 $133.15 USD
Routine Incontinence Management (Supplies and Medication)
Frantz et al. 2003 [39] US Provider 6 mo Barrier cream 1995 $745 $1,312.40 $2,624.80
Disposable briefs $723 $1,273.65 $2,547.30
Bed pads $304 $535.53 $1,071.06
Incontinence management $9.09/day $16.01 $5,843.65
Total incontinence management $1,372 $2,416.94 $4,833.88
Irwin et al. 2009 [36] Canada Provider 1 yr Incontinence pad usage 2005 €56 €60.97 $80.96
Germany Incontinence pad usage €66 €71.41 $94.82
Italy Incontinence pad usage €102 €112.12 $148.88
Spain Incontinence pad usage €102 €114.65 $152.24























Table 2 Total costs per patient, associated with incontinence in general (Continued)
UK Incontinence pad usage €48 €54.95 $72.97
Morris 2005 [33] Australia Provider 1 day Consumables 2003 $6.8 AUD $8.27 AUD *
Total median daily cost for UI $36.2 AUD $44.04 AUD *
Papanicolaou 2005 [35] Germany Payer 1 yr Pad usage 2004 €235 €258.14 $342.78
Conservative care €0 €0 $0
Medications €107 €117.54 $156.08
Spain Pad usage €235 €273.05 $362.58
Conservative care €19 €22.08 $29.32
Medications €88 €102.25 $135.78
UK/Ireland Pad usage €55 €64.26 $85.33
Conservative care €42 €49.07 $65.16
Medications €125 €146.04 $193.93
Prasopsanti et al. 2007 [41] Thailand Patient 1 wk Pad usage 2005 $3.7 USD $4.45 USD $231.40
Subak et al. 2006 [42] US Patient 1 wk Personal care resources 2005 $6.57 USD $7.90 USD $410.80 USD
Tediosi 2000 [37] Italy Payer 1 yr Conservative care 1997 L353.523 L465.526 $618.17
Medications L25.412 L33.463 $44.44
Wefer et al. 2010 [15] Germany Payer 1 yr Urinary reservoir 2006 €0.70/day €0.74 $358.66
Pad usage €1.41/day €1.50 $727.02
Comorbidities
Irwin et al. 2009 [36] Canada Payer 1 yr Comorbidities 2005 €19 €20.69 $27.47
Germany Comorbidities €21 €22.86 $30.36
Italy Comorbidities €9 €9.80 $13.01
Spain Comorbidities €7 €7.62 $10.12
Sweden Comorbidities €35 €38.11 $50.61
UK Comorbidities €13 €14.15 $18.79
Wefer et al. 2010 [15] Germany Payer 1 yr UTI medications 2006 €162.71/yr €173.28 $230.10
Physician Visits and Hospitalizations
Papanicolaou 2005 [35] Germany Payer 1 yr Office visits 2004 €45 €49.43 $65.64
Surgery €95 €104.35 $138.57
Spain Office visits €168 €195.20 $259.20
Surgery €103 €119.68 $158.92
UK/Ireland Office visits €95 €110.99 $147.38























Table 2 Total costs per patient, associated with incontinence in general (Continued)
Tediosi 2000 [36] Italy Payer 1 yr Hospitalizations 1997 L19.814 L26.09 $34.64
Thom et al. 2005 [38] US Payer 1 y Hospitalizations, physician
visits, ED visits
1998 $7,702 USD $12,357.43 USD $12,357.43
Accommodations
Irwin et al. 2009 [36] Canada Payer 1 yr Nursing home 2005 €385 €419.15 $556.59
Germany Nursing home €1,038 €1,130.10 $1,500.65
Italy Nursing home €1,580 €1,720.19 $2,284.22
Spain Nursing home €30 €32.66 $43.37
Sweden Nursing home €562 €611.87 $812.50
UK Nursing home €381 €414.81 $550.82
Prasopsanti et al. 2007 [41] Thailand Patient 1 yr Transportation 2002 $198.12 $238.11 $238.11
* Costs were not extrapolated for this study because costs from the study were costs for sub-acute care, not routine care.
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http://www.hqlo.com/content/11/1/13cope with other symptoms of MS that may be more de-
bilitating when compared with UI. These findings point to
the need for additional research, using disease-specific
instruments to further understand the impact of UI on
the HRQoL of patients with MS or spina bifida.
Evaluating the economic impact of a disease or disease
intervention is becoming increasingly important and
is often one of the factors considered in determining
access to treatment for patients. However, very little eco-
nomic information regarding UI due to NDO or in pa-
tients with MS, SCI, Parkinson’s disease, stroke, or spina
bifida was available, pointing to a need for further re-
search to assess the economic burden of UI in these spe-
cific neurologic populations. Nevertheless, the results do
suggest that the economic burden of UI due to NDO is
substantial for patients, providers and payers, including
direct medical costs, as well as costs for conservative
care, physician/hospital/emergency room services, medi-
cation and complications.
Furthermore, existing studies that describe the eco-
nomic burden of UI have mixed populations, where
costs for UI are lumped with that for OAB as a whole.
We were primarily interested in the economic impact of
UI on an individual level rather than on a population
level, recognizing that the general OAB population is
substantially larger and distinct from patients with un-
derlying neurologic conditions who experience bladder
dysfunction. The studies that provided per-patient an-
nual direct costs for UI from a payer perspective were
mostly conducted in European countries, with annual
costs ranging from $488 to $949 per patient [36]. Mean-
while, studies in the United States indicate that payers
spend as much as $12,353 annually per UI patient for
hospitalizations, physician office visits, outpatient servi-
ces, and emergency department services [38]. Assuming
that 72% (n = 288,000) of the approximately 400,000 MS
patients in the United States have UI [43,44], the esti-
mated direct costs of UI attributable to MS for payers
can be as much as $3.5 billion annually. This represents
substantial incremental costs to an already costly condi-
tion, which has an estimated total annual cost of $10 bil-
lion (2010 US$ inflated from $6.8 billion 1994US$) [45].
Further research on the economic burden of UI in these
patients with chronic, neurologic diseases may be neces-
sary to ensure access to novel therapies that could treat
this condition.
We found a great deal of heterogeneity in the studies
we identified with respect to study design, patient char-
acteristics, and the types of outcome measures used to
characterize the humanistic and economic burden of UI.
This was true both within and across the neurologic
conditions of interest. For example, studies examining
the impact of UI on the HRQoL in MS patients often
used different instruments than studies that assessed theimpact of UI in SCI patients. Similarly, the economic
studies that we identified and reviewed applied different
cost components (e.g., medication costs, diagnostic costs,
office visit costs, labor costs) when quantifying the eco-
nomic burden of UI. As such, the ability to compare the
humanistic and economic impact of UI across neurologic
conditions and across countries was limited. Our results
thus suggest the need for the medical community to reach
a consensus on which tool(s) should be used to assess
HRQoL in patients with neurologic diseases, so that re-
searchers have a standard guideline to follow when de-
signing clinical trials. Use of the same tool across studies
will also facilitate future comparisons.
Our search was limited by the inconsistent termino-
logy used across the literature to describe this subset of
patients with UI due to NDO. As such, studies that used
terms different from ours may not have been generated
in our search. No relevant studies were found in patients
with UI due to urodynamically confirmed NDO, which
is not surprising given that urodynamic evaluations are
not routinely done in patients with urinary symptoms
and that the terminology surrounding lower urinary
tract function has constantly evolved in the last decade
[1]. Furthermore, because the studies we reviewed to as-
sess the economic burden of UI were largely conducted
in the general UI population and not in patients with
MS, SCI, Parkinson’s disease, stroke, or spina bifida, the
results presented here are exploratory and, with the ex-
ception of Wefer et al. [15], not necessarily reflective of
costs associated with treatment of UI due to NDO. Stud-
ies evaluating the economic impact in this subset of pa-
tients are needed.
Important goals of therapy for neurogenic lower urin-
ary tract dysfunction should focus on improving patient
HRQoL by decreasing the most bothersome symptoms
as much as possible [46,47]. Future research is still nee-
ded to clearly assess the burden of UI due to NDO in
patients with MS, SCI, Parkinson’s disease, stroke, spina
bifida, and other neurologic conditions in which UI is
an associated symptom of the disease. These studies
should be carefully designed to include urodynamic
observations to confirm the presence of NDO, consis-
tent and validated HRQoL instruments, and clearly de-
fined cost components.
Conclusion
Incontinent patients with MS, SCI, Parkinson’s disease,
stroke, or spina bifida have impaired HRQoL. In particu-
lar, detriments in physical function, emotional well be-
ing, and social relationships were generally noted across
studies. HRQoL of incontinent patients with neurologic
conditions is also significantly worse compared with
#patients with UI in general or patients with the same
underlying neurologic condition without UI. Our results
Tapia et al. Health and Quality of Life Outcomes 2013, 11:13 Page 14 of 15
http://www.hqlo.com/content/11/1/13also suggest that the economic burden of UI due to
NDO is substantial, and that there is a need for UI treat-
ments that improve HRQoL and alleviate the economic
burden of this condition.
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